• כלים לשירותך
  • כניסה לחשבון שלי
עמוד בית
האיגוד הישראלי
לפרמקולוגיה קלינית רפואה, ייעוץ ומחקר בתרופות Israel Society of Clinical Pharmacology
Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes

להלן תקציר המאמר. הטקסט המלא בקישור:

 

Wang E, Liu Y, Wang Y, Han X, Zhou Y, Zhang L, Tang Y. Comparative Safety of Antipsychotic Medications and Mood Stabilizers During Pregnancy: A Systematic Review and Network Meta-analysis of Congenital Malformations and Prenatal Outcomes. CNS Drugs. 2025 Jan;39(1):1-22. doi: 10.1007/s40263-024-01131-x. Epub 2024 Nov 11. PMID: 39528870; PMCID: PMC11695384.

 

 

Abstract

Background: A network meta-analysis was performed to evaluate the risk of congenital malformations and other prenatal outcomes in fetuses after exposure to antipsychotic medications and mood stabilizers during pregnancy.

Methods: We searched the PubMed, EMBASE, and Cochrane CENTRAL databases up to 15 December 2023, to identify experimental and observational studies comparing antipsychotic and mood stabilizer treatments with control treatments (no exposure). The primary outcome of the study was the incidence of congenital malformations and the secondary outcomes were preterm birth and spontaneous abortion. Additionally, two authors independently assessed the risk of bias in each domain of the included studies using the ROBINS-I tool and evaluated the quality of evidence using the CINeMA rating tool.

Results: The literature search identified 18,334 potential records, and 22 studies involving 3,042,997 pregnant women were ultimately included. Compared with the unexposed group, quetiapine [odds ratio (OR), 1.19; 95% credible interval (CrI), 1.01-1.39], aripiprazole (OR, 1.30; 95% CrI 1.10-1.65), olanzapine (OR, 1.33; 95% CrI 1.11-1.64), risperidone (OR, 1.43; 95% CrI 1.18-1.77), and lithium (OR, 1.61; 95% CrI 1.07-2.30) were associated with a slightly increased risk of congenital malformations. In contrast, lamotrigine (OR, 1.21; 95% CrI 0.86-1.64), ziprasidone (OR, 1.14; 95% CrI 0.73-1.72), and haloperidol (OR, 1.26; 95% CrI 0.90-1.75) did not show significant differences compared with the unexposed group, with narrower credible intervals.

Conclusions: The evidence from this analysis suggests that, overall, quetiapine has the lowest teratogenic risk when used during pregnancy, making it the safer option for pregnant women. Lamotrigine and haloperidol follow closely behind. At the same time, the use of lurasidone and ziprasidone should be approached with caution, and further clinical studies are necessary to better assess their safety.

ברוכים הבאים לאיגוד הישראלי לפרמקולוגיה קלינית

חברי האיגוד מוזמנים להתעדכן בפעילות האיגוד, לצפות בכלים שימושיים לעבודה השוטפת, לשלם דמי חבר ועוד
כניסה לחברי האיגוד
הציבור מוזמן לקרוא מידע עדכני ואמין בתחום הפרמקולוגיה הקלינית, להוריד טופסי הסכמה, לקרוא הנחיות קליניות וניירות עמדה ועוד
איני חבר/ת איגוד